3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Breast Neoplasms
3
Melanoma
2
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Lymphatic Metastasis
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Anus Neoplasms
1
Interventions
Oxaliplatin
180
Capecitabine
174
Fluorouracil
154
Radiotherapy
107
Leucovorin
107
Irinotecan
93
Bevacizumab
69
Surgical Procedures, Operative
49
Cetuximab
39
Drug Therapy
38
Radiation
35
Neoadjuvant Therapy
33
Folfox protocol
29
Chemoradiotherapy
29
XELOX
22
Magnetic Resonance Spectroscopy
21
Chemotherapy, Adjuvant
21
Radiotherapy, Intensity-Modulated
19
Surveys and Questionnaires
17
Proctectomy
16
Biopsy
16
Early Intervention, Educational
14
trifluridine tipiracil drug combination
12
Panitumumab
12
Floxuridine
12
tislelizumab
11
regorafenib
11
Nivolumab
11
Laparoscopy
11
Celecoxib
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Rectal Neoplasms
×
Technetium-99
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled